Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 8/20 | 0.45 |
| ▸ | CCR3 | P51677 | 8/20 | 0.45 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8938967 | 0.95 | HRH1 (0.44) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8936686 | 0.93 | MAOB (0.47) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8937216 | 0.91 | HRH1 (0.42) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8936664 | 0.90 | SMN1; SMN2 (0.48) | HRH1CCR3MAOAMAOBSMN1; SMN2 | |
| SCHEMBL8936719 | 0.90 | HRH1 (0.42) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8939062 | 0.89 | HRH1 (0.41) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8936712 | 0.86 | HRH1 (0.47) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8936820 | 0.86 | ADRB2 (0.43) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8936773 | 0.85 | HRH1 (0.46) | HRH1CCR3MAOAMAOBKCNH2 | |
| SCHEMBL8938964 | 0.85 | HRH1 (0.39) | HRH1CCR3MAOAMAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385047-B1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI SA (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | HRH1 2936/4885CCR3 3890/4885MAOA 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.